Antisense Pharma (Germany) - Dec 2007

MIG AG has invested €27m from its MIG-Fonds 5 in Antisense Pharma GmbH. The fund has a placement volume of €70m, with €10m over-subscription and should close on 31 December 2008. MIG-Fonds 1 and MIG-Fonds 2 invested in a previous funding round closed in 2005. In the current round, MIG AG acquired 9.27% of the nominal capital. Other investors in Antisense Pharma include S-Refit, TechnologiebeteiligungsGesellschaft mbH (now kfw Mittelstandsbank), Technologie Beteiligungsfonds GmbH & Co KG/Bayern Kapital, Global Asset Fund and Global Chance Fund. This financing round is to further advance the company’s product pipeline, in particular the lead product AP 12009. This investment ensures that the company is well funded to carry out clinical studies, including the planned Phase III study in high grade glioma and the Phase I/II in pancreatic carcinoma, malignant melanoma and colorectal carcinoma. No further funding rounds are planned.

Company

Antisense Pharma develops antisense drugs that prevent proteins associated with diseases to originate, allowing the drugs to fight fatal diseases like cancer causally rather than symptomatically. The company’s product pipeline comprises agents against a number of different cancers in various stages of development. The company was founded in 1998 and employs 50 people.

People

Founding managers Dr Karl-Hermann and Dr Reimar Schlingensiepen represented Antisense Pharma during all financing rounds

Sourced from: Deutsche unquote" 94 (Jan 2008)

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Expansion
• Healthcare
• Germany